You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Grabowski J, Pietzke L, Zocholl D, et al
2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer
International Journal of Gynecologic Cancer 2022;32:A309.